Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Steve Fancy who wrote (4873)	7/15/1998 3:41:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 6136

>> Later this month, we will reveal to the financial community an innovative plan to aggressively pursue development of these new HIV therapies, while maintaining steady growth of earnings in our VIRACEPT-driven anti-virals business in the current fiscal year. And we will describe our plan for continuing to pursue novel drugs for treatment of cancer and other serious diseases without loss of momentum. << Can't wait!

To: Steve Fancy who wrote (4873)	7/15/1998 8:19:00 PM
From: Oliver & Co	Read Replies (1) \| Respond to of 6136

Thank you for the post. The letter is good and goes to the positives of Viracept, however, we know that investors at large know nothing about these drugs, and they trust anal-ysts. I believe there are people playing with the stock, how else could you explain that AGPH goes up before news and then down with good news. This company has been making money, and yet you see it going down when other companies that are not making anything go up. Entremed went up astronomically with their press release on their angiogenesis drug, that is not even on Phase I, and AGPH got nothing when they said their drug was on phase II-III testing. Also, I do not know why there are so many against this company, from Henry Niman to Mr. Crosson from MOntgamery. JLL